Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. by Rögnvaldsson, Sæmundur et al.
Rögnvaldsson et al. Blood Cancer Journal           (2021) 11:94 
https://doi.org/10.1038/s41408-021-00480-w Blood Cancer Journal
ART ICLE Open Ac ce s s
Iceland screens, treats, or prevents multiple
myeloma (iStopMM): a population-based screening
study for monoclonal gammopathy of
undetermined significance and randomized
controlled trial of follow-up strategies
Sæmundur Rögnvaldsson 1, Thorvardur Jon Love1, Sigrun Thorsteinsdottir 1,2, Elín Ruth Reed1,
Jón Þórir Óskarsson 1, Íris Pétursdóttir1, Guðrún Ásta Sigurðardóttir1, Brynjar Viðarsson3, Páll Torfi Önundarson1,3,
Bjarni A. Agnarsson1,3, Margrét Sigurðardóttir3, Ingunn Þorsteinsdóttir3, Ísleifur Ólafsson3, Ásdís Rósa Þórðardóttir1,
Elías Eyþórsson3, Ásbjörn Jónsson3, Andri S. Björnsson4, Gunnar Þór Gunnarsson1,5, Runólfur Pálsson1,3,
Ólafur Skúli Indriðason1,3, Gauti Kjartan Gíslason 1, Andri Ólafsson1, Guðlaug Katrín Hákonardóttir1, Manje Brinkhuis 1,
Sara Lovísa Halldórsdóttir1, Tinna Laufey Ásgeirsdóttir6, Hlíf Steingrímsdóttir3, Ragnar Danielsen3, Inga Dröfn Wessman4,
Petros Kampanis7, Malin Hulcrantz8, Brian G. M. Durie9, Stephen Harding7, Ola Landgren 10 and
Sigurður Yngvi Kristinsson 1,3
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based
screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or
Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a
randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples
are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to
three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy.
Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the
study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of
life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in
the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the
data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of
screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.
Introduction
Monoclonal gammopathy of undetermined significance
(MGUS) is characterized by the presence of monoclonal
immunoglobulins (M proteins) or an abnormal ratio of free
immunoglobulin light chains (FLC) in the blood1. MGUS
can be classified by the type of M proteins present. Non-
IgMMGUS is the most common type and is defined by the
presence of IgG, IgA, and rarely IgD or IgE M proteins2.
IgM MGUS is defined by the presence of IgM M proteins3.
Light-chain (LC) MGUS is defined by an abnormal
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FLC-ratio, indicating an excess of monoclonal FLCs in the
absence of M proteins4. Non-IgM MGUS and LC-MGUS
are caused by monoclonal bone marrow plasma cells
(BMPCs) and are the precursor of multiple myeloma
(MM), a malignancy of BMPCs5,6. IgM MGUS is caused by
monoclonal lymphoplasmacytic lymphocytes and is a pre-
cursor to other lymphoproliferative disorders (LP), most
notably Waldenström’s macroglobulinemia (WM), and
rarely MM3. In addition, MGUS of all types, especially LC-
MGUS, can precede amyloid light chain amyloidosis (AL)7.
Prior studies suggest a 1% annual risk of progressing from
MGUS and LC-MGUS to frank malignancy1,3,4,8.
Before progressing to MM or WM, MGUS is believed to
pass through a smoldering MM or WM phase (SMM and
SWM), which is associated with a higher disease burden
than MGUS and LC-MGUS but without MM or WM
related organ damage1. Smoldering disease carries a
higher risk of progression to active disease than MGUS.
Retrospective data from the Mayo Clinic suggest that the
risk of progression from SMM to MM is 10% per year for
the first five years9, and that the risk of progression of
SWM to WM is 60% within 10 years10.
Currently, consensus guidelines recommend indefinite
follow-up in MGUS, SMM, and SWM. However, there is
no data available from prospective studies or randomized
trials regarding optimal clinical management1,11–13. Three
recent observational studies from Sweden and the US
have consistently demonstrated that individuals with
known MGUS prior to the diagnosis of MM have 13–15%
better overall survival in MM14–16. These observations
indicate that clinical follow-up of precursor disease leads
to earlier detection and diagnosis of MM, resulting in
fewer patients presenting with symptomatic end-organ
damage at the time of MM diagnosis, which may have
contributed to the observed better overall survival.
In the clinical setting, the optimal timing of therapy in
MM has been a subject of debate. Traditionally, therapy has
been reserved for those with MM-related end-organ
damage, however, in 2014 the definition of MM was
expanded to also include myeloma-defining biomarkers in
asymptomatic individuals8. With the advent of newer, more
effective, and less toxic drugs, survival has improved dra-
matically in MM17–19. Three separate randomized con-
trolled trials starting therapy at the stage of SMM have
shown improved progression-free survival, and one study
showed superior overall survival20–22. Importantly, these
studies have shown more favorable toxicity profiles than
earlier trials23. In light of these findings some authors now
recommend early treatment in high-risk SMM24,25. How-
ever, only 2.7–6.0% of MM patients have previously iden-
tified precursor disease, which limits the implementation of
early treatment in most MM patients14,16. This raises the
question of whether population-based screening and
follow-up of MGUS could improve the outcomes in MM by
identifying candidates for early treatment. However, there is
no evidence supporting the implementation of asympto-
matic screening for MGUS, and screening is not currently
recommended. To address this question, we have launched
a population-based screening study with a subsequent
randomized controlled trial (RCT) evaluating the risks and
benefits of screening and follow-up of MGUS patients.
Here, we describe the design and recruitment of the
Iceland Screens, Treats, or Prevents Multiple Myeloma
study (iStopMM), a population-based screening study of




The study protocol, all information material, biobank,
and questionnaires were approved by the Icelandic
National Bioethics Committee (Number 16–022, date:
2016-04-26) with approval from the Icelandic Data Pro-
tection Agency. Access to national healthcare registries
has been approved by the Icelandic Directorate of Health
and the Icelandic Cancer Society. The study was pre-
registered on ClinicalTrials.gov (ClinicaTrials.gov identi-
fier: NCT03327597).
Recruitment and screening
The study’s inclusion criteria were being born in 1975
or earlier and residing in Iceland on the 9th of September
2016, as registered in the Icelandic National Registry.
Eligible individuals were invited to participate in the
iStopMM study (n= 148,711). A letter containing a
detailed information brochure and consent form was
mailed to them and an extensive campaign on social and
conventional media was launched introducing the study
to the Icelandic public. This campaign was followed by
phone calls to those who had not yet signed up for the
study. Participants could provide informed consent
through three different mechanisms: (1) returning a
signed informed consent form by mail, (2) registering
electronically using a participation code included in the
invitation letter, or (3) through a secure internet gateway
provided by the Icelandic government (island.is), which is
accessible to all residents through a secure electronic
authentication process. The only exclusion criterion was
previously known LP, other than MGUS.
After enrollment, serum samples for screening are col-
lected alongside the collection of blood during clinical
care in the universal Icelandic healthcare system, includ-
ing blood banks (Fig. 1). The study team in collaboration
with Landspítali—The National University Hospital of
Iceland (LUH), developed an electronic system linking
participant data to the central laboratory network of all
major and smaller urban healthcare institutions, which
covers at least 92% of all Icelandic residents. The system
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notifies healthcare workers to take an extra blood sample
for the study at the point of clinical blood sampling. For
smaller rural institutions and private clinics, a manual
system was developed whereby laboratory technicians
crosslink left-over samples marked for destruction to
registered participants and in some cases ask their
patients if they are participants in the study and draw an
additional sample for the study. To capture samples from
participants who do not require clinical blood sampling,
an active sampling drive was initiated after three years of
passive sample collection.
All samples are sent to the clinical laboratory at LUH in
Reykjavik, Iceland where serum is aliquoted into identical
sample tubes and assigned an anonymous study identifi-
cation number. The laboratory uses TC automation and
aliquoter (Thermo Scientific®, MA, USA) for sample
handling. Samples are then sent to The Binding Site
laboratory in Birmingham, UK where all samples are
screened for M protein by capillary zone electrophoresis
(CZE; Helena Laboratories, Texas, USA) and for FLC,
immunoglobulins (IgG, IgA, and IgM), and total protein
by Freelite® and Hevylite® assays performed on an
Optilite® turbidimeter (The Binding Site Group Ltd,
Birmingham, UK). Immunofixation electrophoresis (IFE;
Helena Laboratories, TX, USA) is performed on samples
with clear or suspected M protein bands by CZE and/or
abnormal FLC results. The CZE and IFE gels are assessed
independently by at least two experienced observers.
Randomization and study arms
Participants with an M protein or pathological FLC
results are considered eligible for the RCT and are ran-
domized into three study arms in a dynamic, non-
predetermined manner (Fig. 2). To avoid skewed dis-
tribution of high-risk MGUS and LC MGUS, randomiza-
tion is carried out by blocks of having an M protein >1.5 g/
dL and having LC-MGUS. Participants in arm 1 are not
informed of their MGUS status and continue to receive
conventional healthcare as if they had never been screened.
Arm 2 follows current guidelines for follow-up, stratified by
low and non-low risk MGUS1. Arm 3 follows a more
intensive strategy that is not risk-stratified (see below).
Participants with an M protein ≥3.0 g/dL or an FLC
ratio ≥100 are not eligible for randomization but are all
called in for evaluation since they have, by definition,
more advanced disease than MGUS1,8,10. Participants with
previously diagnosed MGUS cannot be randomized to
arm 1, as they are aware of their MGUS status, and are
thus randomized to arms 2 or 3 and will not be included
in comparisons with arm 1.
Initial assessment and follow-up
Initial assessment and follow-up of participants in arms 2
and 3 and participants diagnosed with more advanced
disease (SMM, SWM, MM, AL, or other LP) at screening is
performed in the iStopMM study clinic in Reykjavík, Ice-
land. Temporary clinics are also regularly established in
Fig. 1 Methods of blood sample acquisition. A and B describe passive sampling starting during the fall of 2016, and C describes active sampling
beginning during the fall of 2019. 1: Reykjavik Capital Area, Akureyri, Ísafjörður, Reykjanes Peninsula, Akranes, Healthcare Institution of Northern
Iceland, Healthcare Institution of South Iceland, blood banks 2: Neskaupsstaður, Healthcare institution of West Iceland, Healthcare Institution of East
Iceland. 3: Available for all Icelandic residents.
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Akureyri, Ísafjörður, Húsavík, and Egilsstaðir for complete
geographical coverage. All participants who are called into
the clinic are seen by specialized study nurses and those
with more advanced disease are also seen by a physician.
The participants undergo a clinical interview and thorough
clinical examination and are given detailed oral and written
information about their diagnosis and prognosis.
Participants in arm 2 with non-IgM MGUS or LC-
MGUS are stratified by having low-risk MGUS or not.
These participants are then followed according to guide-
lines including plain skeletal surveys and bone marrow
sampling for those with non-low risk MGUS or when
clinically indicated1. All participants in arm 3 follow an
intensive follow-up schedule regardless of risk, including
bone marrow sampling and whole-body low-dose compu-
terized tomography (WB-LDCT). Participants in arm 2 and
3 with IgM MGUS undergo a computerized tomography
(CT) of the abdomen. Diagnostics and follow-up intervals
for arms 2 and 3 are shown in Table 1. Participants with
smoldering or active disease at baseline or later are fol-
lowed according to guidelines. This includes intensive
follow-up every 4 months or sooner if clinically indicated
with annual bone marrow samples and WB-LDCT, as well
as magnetic resonance imaging (MRI) if no bone lesions
are seen on WB-LDCT. Participants who develop inter-
mediate to high-risk SMM, MM, or other related disorders
that require treatment are offered participation in a treat-
ment trial (ClinicalTrials.gov identifier: NCT03815279) or
referred to the hematology unit at LUH or Akureyri Hos-
pital for evaluation, treatment, and follow-up.
To detect AL, urine samples are tested for proteinuria in
participants visiting the study clinic. In addition,
participants in arm 3 and those with more advanced
disease are tested for cardiac markers (Table 1). Those
with significant proteinuria and decreased kidney function
of unclear etiology are referred to a nephrologist for
further evaluation. Those with abnormal cardiac markers
not explained by known comorbidities are referred to a
cardiologist for clinical evaluation and echocardiography.
Bone marrow biopsies are stained with Congo red for the
presence of amyloid fibrils in all these cases and another
testing for AL is performed as clinically indicated.
After each visit, participant’s test results and clinical
findings are thoroughly reviewed by the primary inves-
tigator and the clinic staff with respect to their disease
status and progression at regular clinical decision meet-
ings. Additional testing including repeat bone marrow
sampling, imaging, blood sampling, or clinical evaluation
is ordered as clinically indicated at or between protocol
visits. Diagnoses of SMM, MM, SWM, WM, AL, and
other LP are made according to current diagnostic
criteria1,8,26,27.
Imaging
Plain radiographs, WB-LDCT, and CT of the abdomen
are performed in LUH and Akureyri Hospital. MRI is
performed in LUH and Akureyri Hospital. All radiological
images are reviewed independently by two physicians, one
in specialty training and a senior radiologist at LUH. The
radiological assessments are blinded and any discordance
in findings is discussed and solved by the two physicians.
Bone marrow samples
Bone marrow sampling is performed by study nurses
that have been trained, both locally and in an accredited
facility in the United Kingdom (The Royal Marsden
Hospital, London, UK). Samples are collected as bone
marrow smears and as trephine biopsies. Bone marrow
smears are stained with Giemsa stain and jointly evaluated
by two senior hematologists at LUH reporting the per-
centage of BMPCs or lymphoplasmacytic lymphocytes,
lymphoid infiltrates, and sample quality. Trephine biop-
sies are stained with hematoxylin and eosin, as well as for
CD138 before being evaluated by two senior hemato-
pathologists at LUH. The sample with the higher per-
centage of BMPCs/lymphocytic infiltration at each
sampling time is used to guide follow-up.
Questionnaires
Immediately following informed consent, participants
were asked to complete questionnaires on psychiatric
symptoms (e.g., anxiety and depressive symptoms) and life
satisfaction to establish a baseline prior to screening28–30.
Throughout the study period, all participants, regardless
of screening status, are asked to complete the same
questionnaires electronically at predefined intervals, as
Fig. 2 A flowchart outlining the study design for screening and
randomization of individuals with MGUS. MGUS Monoclonal
gammopathy of undetermined significance, SPEP Serum protein
electrophoresis, FLC Free light chain assay, SMM Smoldering multiple
myeloma, MM Multiple myeloma.
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well as additional questionnaires on psychiatric health,
pain, neuropathic symptoms, and more (Table 2).
Those who visit the study clinic (arms 2 and 3, and indi-
viduals with more advanced disease) answer more extensive
questionnaires at each clinic visit and annually. Those who
are randomized to arm 1 or are screened negative continue
to receive the same annual questionnaires. One-time ques-
tionnaires, e.g., baseline characteristics, employment history,
resilience, social support, and adverse childhood experiences
are sent to all participants by email (Table 2).
Currently, 72 918 (90%) of all participants have provided
their email addresses. All non-valid email addresses are
reviewed by study staff and participants who visit the study
clinic are asked to provide a valid email. Participants
are reminded to answer the questionnaires in three
separate emails.
Table 1 Clinical assessment, imaging, and laboratory studies included for participants in the different study arms of the
iStopMM study as per protocol.
Test Arm 2–low risk and
LC-MGUS
Arm 2–non-low risk Arm 3–All SMM and SWM MM and WM




Each visit Each visit Each visit Each visit At diagnosis








– – Each visit Each visit At diagnosis
TnT
pro-BNP




As clinically indicated 0 months
Except if LC
0 and 60 months Annually At diagnosis
Urine
Protein dipstick First visit First visit – – –
UPEP If positive dipstick or if
previously abnormal





– – Annually Annually At diagnosis
ECG – – Annually Annually At diagnosis
Imaging
WB-LDCT – – 0 and 60 months in LC- and
non-IgM
Annually in LC- and
non-IgM
At diagnosis of MM
Plain X-ray of bones As clinically indicated First visit in LC- and
non-IgM
– – –
CT abdomen – First visit to IgM 0 and 60 months in IgM Annually in IgM At diagnosis of WM
MRI of bones – – – As clinically indicated –
Follow-up Every 2–3 years Annual Annual Every 4–6 months Single-visit
Note that additional sampling and imaging were permitted as clinically indicated and decided at regularly scheduled clinical decision meetings.
SMM smoldering multiple myeloma, SWM smoldering Waldenströms macroglobulinemia, MM multiple myeloma, WM Waldenströms macroglobulinemia, SPEP serum
protein electrophoresis, FLC free light chains, CBC complete blood count, CRP C-reactive protein, LDH Lactate dehydrogenase, ß2M ß-2-microglobulin, TnT Troponin T,
pro-BPN pro-Brain natriuretic peptide, UPEP Urine protein electrophoresis, ECG electrocardiogram, WB-LDCT whole-body low-dose computerized tomography, CT
Computerized tomography, MRI magnetic resonance imaging, LC Light chain.
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Registry crosslinking
Several national healthcare-related registries exist in
Iceland that can be accurately crosslinked using a
government-issued national identification number. Data
from these registries are linked to all participants in the
iStopMM study at least twice each year. The following
registries are linked to the study datasets: (1) The Ice-
landic Cancer Registry includes information on all cancers
diagnosed in Iceland. It has been mandatory for all phy-
sicians and pathologists to register diagnoses of cancer
Table 2 Questionnaires sent to participants by email or answered at the study clinic.
Questionnaire Subject Validated? All Arm 1 and normal
screening
Arm 2 and 3 and
advanced diseasea
At registration One time Annually One time Each visit
Background
Anthropomorphic data Weight, height etc. NA ✓ ✓
Social historyb Socioeconomic status NA ✓ ✓
Medical historyc Medical history ✓ ✓
Habitsd Environment NA ✓ ✓
Industrial exposure Environment NA ✓ ✓
Quality of life
PHQ9 Depression Yes ✓ ✓ ✓
GAD-7 Anxiety Yes ✓ ✓ ✓
SWLS Quality of life Yes ✓ ✓ ✓
Other questions of happiness and
wellbeing
Quality of life No ✓ ✓ ✓
SF-36 Health-related quality of life Yes ✓ ✓
PSS-10 Stress and anxiety Yes ✓ ✓
PCL-5 (MGUS specific) PTSD from MGUS diagnosis Yes ✓
PCL-5 (nonspecific) PTSD other Yes ✓
Symptoms
BPI Pain Yes ✓ ✓
NSS Neuropathy Yes ✓ ✓
DN4 Neuropathy Yes ✓ ✓
Symptoms of PMR PMR No ✓ ✓
Social background
MSPSS Social support Yes ✓ ✓
CD-RISC-10ICE Resilience Yes ✓ ✓
ACE Childhood traumatic events Yes ✓ ✓
LEC Lifetime traumatic events Yes ✓ ✓
Note that all participants were asked to answer four questionnaires when providing informed consent electronically or if they provided an email address in their
written consent form.
Questionnaires were not sent to participants who did not provide an email address and were not called into the study.
PHQ9 patient health questionnaire, GAD-7 General anxiety disorder, SWLS satisfaction with life scale, SF-36 36-item short-form survey, PSS-10 perceived stress scale,
PCL-5 post-traumatic stress disorder checklist for DSM-5, BPI brief pain inventory, NSS neuropathy symptom scale, DN4 Douleur neuropathique. PMR polymyalgia
rheumatica, MSPSS Multidimensional scale of social support, CD-RISC-10ICE Connor-Davidson resilience scale. ACE adverse childhood events. LEC Lifetime events
checklist.
✓Showing the timing of the questionnaire in that row is the time/frequency assigned to that column.
aIncluding MM, WM, SMM, and SWM.
bEmployment, marital status, education, income, and residence.
cIncluding obstetric history for women.
dIncluding smoking and alcohol intake.
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since 1955 and it is virtually complete with high diag-
nostic accuracy and timeliness31; (2) The Icelandic Causes
of Death Registry includes all deaths in Iceland including
the date and the presumed causes of death. Registration
has been mandatory since 1971; (3) The Icelandic Pre-
scription Medicines Registry includes all prescriptions,
including whether the prescriptions were filled or not. in
Iceland since 2002; (4) The Icelandic Hospital Discharge
Registry includes all inpatient admissions in Iceland from
1999 with the dates of admission and discharge, as well as
international classification of diseases (ICD) codes for the
diagnoses made by treating physicians. The registry also
includes outpatient visits at hospitals, including emer-
gency rooms since 2010; (5) The Icelandic Registry of
Primary Health Care Contacts includes all primary care
visits and registered ICD-coded diagnoses for all primary
care encounters in Iceland since 2004; (6) The Icelandic
Central Laboratory Database comprises laboratory test
results from all major clinical laboratories in Iceland
stored in a central database since 1999, including all blood
tests for participants prior to participation and during
follow-up in the study; (7) All medical records at LUH, the
only tertiary care medical center in Iceland and the gen-
eral acute care hospital for the vast majority of Icelandic
residents. This includes clinical notes, anthropometric
data, written radiology and pathology reports, micro-
biology and virology test results, and all other docu-
mented clinical data.
Biobanking
Blood samples drawn at each clinic visit are biobanked
including cell-free plasma, serum, and plasma. Bone
marrow samples are collected for biobanking in parallel to
bone marrow sampling. Urine and blood in Blood-RNA
tubes (PAXgeneTM) tubes and in mononuclear cell pre-
paration tubes (BD Vacutainer® CPTTM) are collected at
sparser timepoints (Table 3). Samples are processed on-
site and aliquoted at the study laboratory in Reykjavík,
Iceland, and bone marrow samples separated into plasma
and buffy coats. The bone marrow buffy coats from non-
IgM MGUS and LC-MGUS are further separated into a
plasma cell-enriched CD138+ fraction and a CD 138−
fraction by Magnetic-activated cell sorting (MACS) using
CD138 MicroBeads and an autoMACS pro cell separator
(Miltenyi Biotec, Bergisch Gladbach, Germany). All cell
fractions are cryopreserved and stored in liquid nitrogen.
Other biobanking samples are frozen and stored in a
secure state-of-the-art robotic biobanking facility in Rey-
kjavík, Iceland, and cataloged using unique study identi-
fication numbers.
Study monitoring
A study monitor was appointed to review the study
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for compliance with relevant good clinical practice (GCP)
principles. An independent data monitoring committee
was established including two clinicians and a statistician
that are not associated with the study. Interim analyses
assessing safety and efficacy data are performed biannually.
Additional interim analyses are scheduled when 500 sub-
jects with MGUS have been followed for 6 months and
when 100 participants with MGUS have died. When par-
ticipants who have been randomized have been followed
for five years, or if interim analysis shows a difference in the
overall survival between arm 1 compared to arms 2 and 3,
arm 1 will be discontinued. At that time the participants in
arm 1 are unblinded to their MGUS status and offered a
choice between randomization to arms 2 or 3, or clinical
follow-up in the Icelandic healthcare system.
Study endpoints
The primary endpoint of the study is the overall survival
of individuals with MGUS receiving follow-up (arms 2
and 3) compared to those not receiving any follow-up
within the study (arm 1) after 5 years of follow-up. Sec-
ondary endpoints are cause-specific survival due to MM
or other LPs, psychiatric health and well-being, and cost-
effectiveness of screening. In addition, study data will be
crosslinked to registries and samples in the biobank
providing a large dataset for future studies.
Assuming that 3360 individuals with MGUS are iden-
tified and the hazard ratio (HR) for the primary outcome
is 0.81 as previously described32 the study has 77.2%
power to reject the null hypothesis of HR= 1 at 5 years of
follow-up and 89.3% power at 7 years of follow-up at an
alpha level of 0.05.
Results
A pilot recruitment phase was started in Akranes
(population 7411) in Western Iceland on September 15th,
2016, to ensure that informational materials and pro-
cesses of recruitment functioned as planned. After minor
adjustments, the whole-nation recruitment phase com-
menced on November 15th, 2016, and continued until
February 20th, 2018.
A total of 148,704 individuals born in 1975 and earlier
resided in Iceland when enrollment started, constituting the
target population of the study. During the 15 months of
recruitment, a total of 80,759 (54.3%) individuals provided
informed consent for participation in the study (Fig. 3).
Written informed consent was provided by 26% of parti-
cipants while 74% provided informed consent electronically.
Of registered participants, 46% were male and 54%
female constituting participation rates of 51% and 58%,
respectively. Participation was highest (64%) among those
between the ages of 60–79 but was lower (46%) in those
between the ages of 40–49 and lowest (18%) among those
over the age of 90 years old. The majority of participants
(59%) were residents of the Reykjavik Capital Area with
18% and 23% of participants residing in other urban
centers (more than 5000 inhabitants) and in rural areas,
respectively. The participation rates were higher among
those not residing in the Reykjavík Capital Area (60%
versus 51% in the Reykjavík Capital Area; Table 4).
A total of 548 (0.7%) of participants had previously
known LP before enrollment and were therefore excluded
and 246 (0.3%) had previously known MGUS before
enrollment. At the close of study enrollment on February
20th, 2018, a total of 190,382 hospital admissions since
Fig. 3 Participant enrollment over the recruitment period. The light green line represents the end of the pilot period and the initiation of
nationwide recruitment.
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1999, 8,187,805 primary health care visits since 2004,
10,328 cancer diagnoses since 1955, and 15,839,376
medication prescriptions in the national registries.
Discussion
The iStopMM study is the first nationwide population-
based, prospective screening study, and RCT among
individuals with MGUS and the disorders it precedes. A
total of 80,755 participants, 54.3% of the whole Icelandic
population, born 1975 and earlier have enrolled in the
iStopMM study. The high participation rate can be
attributed to the extensive promotional effort undertaken
in social and conventional media across Iceland where
participation in scientific studies has historically been
high33–35. In addition, using innovative solutions such as
electronic informed consent and sampling parallel to
clinical blood draws for screening, participants could
easily sign-up and did not need to schedule a blood draw
specifically for the study.
MGUS was first described as “benign gammopathy” by
Dr. Jan Waldenström in 196036 and later defined as
MGUS by Dr. Robert Kyle in 197837. Since then, screening
studies in Olmstead county2 and the National Health and
Nutrition Examination Survey in the US38,39, in Ghana40,
and the PLCO-NCI Cancer Screening Trial41 have fun-
damentally changed our understanding of MGUS and the
disorders it precedes. These studies have provided
important evidence directing the course of clinical and
basic science in the field and guided the management of
individuals with MGUS. The iStopMM study builds upon
these studies with nationwide screening and detailed
clinical assessment and follow-up of individuals with
MGUS within an RCT. Through this design, the iStopMM
study aims to evaluate the potential harms and benefits of
population-based screening while also providing evidence
for the optimal diagnostic approach and follow-up of
individuals with MGUS.
Guidelines currently recommend screening for cancers
of the breast, cervix, colon, lungs, and prostate42. Cancer
screening is controversial due to the high number of
individuals needed to be screened to improve clinical
outcomes and the high level of false-positive results that
may lead to overtreatment, a lower sense of wellbeing, and
even psychiatric illness43. In fact, a diagnosis of active
cancer, including MM, has been associated with psy-
chiatric disorders44 and suicide45,46. However, the role of
screening in these outcomes is not known and such
effects have not been shown to result from the diagnosis
of pre-cancerous conditions like MGUS47,48. All partici-
pants of the iStopMM study are closely monitored for
their psychiatric well-being using multiple psychome-
trically sound questionnaires. This will provide high-
quality evidence on the potential psychological harms of
MGUS screening that may have wider implications for
cancer screening in general. Widely accepted criteria for
when population-based disease screening is appropriate
was developed by Wilson and Jungner in 196849 and
recently expanded further50. As detailed in Table 5, most
of these criteria are already filled by MM. However, there
are still important questions that need to be answered,
most notably whether the benefits of screening outweigh
Table 4 The age, sex, and geographical distribution of
participants and the target population, as well as available
national registry data at the close of study recruitment.
Registered participants Target population
n 80,759 148,704
% females 54% 51%
median agea 59 57






40–49 (%) 21.2%/23.7% 27.4%/26.0%
50–59 (%) 27.7%/29.9% 29.4%/28.7%
60–69 (%) 28.4%/26.1% 23.4%/22.4%
70–79 (%) 16.6%/14.4% 12.9%/13.3%
80–89 (%) 5.7%/5.3% 6.0%/7.8%
>90 (%) 0.4%/0.5% 0.9%/1.8%
Place of residence
Reykjavik Capital Area 58.7% 62.9%
Other urban centersb 17.5% 15.6%
Rural 23.3% 21.1%
Missing 0.6% 0.4%
Known MGUSc 246 (0.3%) –
Previous LPd 548 (0.7%) –
Data from registriese
n hospital admissions 190,382 –
n primary care visits 8,187,805 –
n cancers diagnoses 10,328 –
n prescriptions 15,839,376 –
aAge at the time of study initiation on September 9th, 2016.
bUrban centers with >5000 inhabitants outside the Capital area.
cAs registered before study enrollment in the Icelandic Cancer Registry since
1955, Icelandic Central Laboratory Database since 1999. and a registry of MGUS
cases at Icelandic Private Clinics.
dAs recorded before study enrollment in the Icelandic Cancer Registry
since 1955.
eAs recorded in national registries at the close of study enrollment on February
20th, 2018.
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Table 5 Application of the Wilson and Jungner criteria and the additional recently proposed emerging criteria to
multiple myeloma.
Criteria Applies to MM? Comment
Original criteria49
The condition sought should be an important health problem Yes MM is the second most common hematological malignancy
with 31,810 new cases and 12,770 attributed deaths in 2018 in
the United States alone53
There should be an accepted treatment with recognized disease Yes Treatment for MM is widely available and international
organizations recommending specific care for MM54
Facilities for diagnosis and treatment should be available Yes This at least applies to developed countries
There should be a recognizable or early symptomatic stage Yes MGUS and SMM are clearly established entities1 and precede all
cases of MM5,6
There should be a suitable test or examination Yes SPEP, IFE, and FLC assays are sensitive and specific tests for MM
and its precursors and can easily be repeated to confirm the
diagnosis55
The test should be acceptable to the population Yes Screening is done by a blood test which is widely acceptable
The natural history of the condition, including development from
latent to declared disease, should be adequately understood
Yes Although there is still much to learn about the underlying
pathogenesis of MM, a wealth of literature on the subject
exists56. Furthermore, the natural history of MM and its
development from precursor disorders is adequately
understood with studies including decades of follow-up
available57
There should be an agreed policy on whom to treat as patients Yes Although this is currently a moving target, there are clear
guidelines on whom to treat, i.e., those with end-organ damage
or myeloma defining events. In light of recent evidence,
however, treatment might become available at even earlier
stages20,21,58. If and when such early treatment is appropriate,
there are institutions in place that will include such treatment in
their guidelines
The cost of case-finding (including diagnosis and treatment of
patients diagnosed) should be economically balanced in relation
to possible expenditures on medical care as a whole
Unknown There are currently no screening studies available for MM and its
precursor conditions and a cost-benefit analysis is not available.
This will be addressed as part of the iStopMM study
Case finding should be a continuing process and not a “once and
for all” project
Yes Since blood sampling for screening can be carried out at any
time MM screening can be a continuing process
Emerging screening criteria50
The screening program should respond to a recognized need Yes Although survival in MM has dramatically improved in recent
years17–19 the disease remains a major burden on affected
individuals and healthcare systems59
The objectives of screening should be defined at the outset Yes The objectives of screening for MM are clear: providing earlier
treatment for MM
There should be a defined target population Unknown Currently, a well-defined target population for screening does
not exist. This is addressed with regards to age, sex, and various
other measures in the iStopMM study. However, due to the
dominant white ethnicity of the Icelandic population, race
cannot be addressed in the iStopMM study. Another study, the
PROMISE study, focuses on the impact of screening in
individuals of African descent. (ClinicalTrials.gov Identifier:
NCT03689595)
Rögnvaldsson et al. Blood Cancer Journal           (2021) 11:94 Page 10 of 13
Blood Cancer Journal
the associated harms and costs. The results of the
iStopMM study will provide answers to these outstanding
questions on whether population-based screening is
warranted in MM.
Current clinical consensus guidelines for MGUS are not
based on RCT data but rather on observational studies
and expert opinions1,11–13. By conducting an RCT of
different follow-up strategies, the iStopMM study aims to
provide high-quality evidence for the optimal follow-up in
MGUS. This includes the role of clinical assessment,
questionnaires on symptoms, imaging, blood, bone mar-
row, and urine sampling. In addition, for research pur-
poses, these clinical parameters are crosslinked to past
and future testing in the Universal Icelandic healthcare, as
well as health-related endpoints such as all cancers and
death. Furthermore, novel testing modalities like next-
generation flow cytometry of plasma cells in the blood
and bone marrow51 and their microenvironment, mass
spectrometry52, and single-cell, and germline genetics will
be utilized to investigate their role in clinical management
and to gain insight into the pathogenesis of MGUS and
the biological processes involved in its progression to
more advanced disorders. This is even further supple-
mented by the study´s extensive biobank, which includes
blood, bone marrow, and urine samples collected
repeatedly over the study period that can be retrieved at a
later date for all participants or for participants of parti-
cular interest. With this extensive dataset and biobank,
the iStopMM results will generate one of the most
complete datasets on MGUS to date, providing unique
opportunities for future studies.
The iStopMM study has some limitations. Firstly, the
study is performed in Iceland which has a highly geneti-
cally homogenous white population and generalization of
the study findings in non-white populations is somewhat
limited. Secondly, by offering early treatment the natural
history of MGUS progression to MM is affected. The
main ethical issue of the study is that participants in arm 1
are not made aware of their MGUS status. These parti-
cipants will not gain the potential benefits of screening
but will also not be exposed to the potential harms of
screening including psychological harms. These partici-
pants will continue receiving care in the universal Ice-
landic healthcare system and may be diagnosed there.
Importantly, participants with markers of advanced dis-
ease at screening are not randomized to arm 1. Arm 1 will
also be followed closely in regular interim analyses and
will be unblinded if shown to have inferior survival.
In conclusion, using a novel and innovative recruitment
methodology, including electronic informed consent and
sampling parallel to clinical blood draws, as well as social
and conventional media campaigns, over 80,000 indivi-
duals, more than half of the eligible Icelandic population,
have enrolled in the iStopMM study. By population-based
screening, follow-up of individuals with MGUS within an
RCT, and early treatment in MM, the iStopMM study will
generate large datasets and sample collections that will
impact our basic understanding of MGUS and the
Table 5 continued
Criteria Applies to MM? Comment
There should be scientific evidence of screening program
effectiveness
Unknown The objective of the iStopMM study is to provide this evidence
The program should integrate education, testing, clinical services,
and program management
Yes There are excellent patent resources available in MM and its
precursor disorders. Any screening program would be able to
fulfill this criterion
There should be quality assurance, with mechanisms to minimize
potential risks of screening
Yes This organizational issue can be solved in MM screening since
there are clear response criteria60 and accepted relevant
endpoints like survival available for MM
The program should ensure informed choice, confidentiality, and
respect for autonomy
Yes This is a practical issue that does not require scientific proof of
concept, although such proof is provided in the iStopMM trial
The program should promote equity and access to screening for
the entire population
Yes Since the cost of MM screening is relatively low and requires no
specialized equipment at the point of patient care, equity in
testing is therefore feasible. Follow-up for precursor disorders
and treatment for MM can however be expensive and could
lead to inequity in non-universal healthcare systems
Program evaluation should be planned from the outset Yes The practical issue of evaluation is possible for MM as proven by
the methodology described above
The overall benefits of screening should outweigh the harm Unknown This is the principal study objective of the iStopMM study
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disorders it precedes. Furthermore, it holds promise to
fundamentally change the paradigm of MM treatment
from late treatment in MM patients with end-organ
damage to screening and early intervention, improving
the overall survival and quality of life for patients
worldwide.
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